Home › Cancro al seno › Ohio
Studi clinici su Cancro al seno nello stato di Ohio
79 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Ohio.
Città nello stato di Ohio
- Columbus39 studi
- Cleveland35 studi
- Cincinnati25 studi
- Akron13 studi
- Dayton7 studi
- Toledo6 studi
- Youngstown4 studi
- Findlay4 studi
- Newark3 studi
- Wooster3 studi
- Parma3 studi
- Zanesville3 studi
- Sandusky3 studi
- Mansfield3 studi
Testo ufficiale dello studio (inglese)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- e altri 44
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
- Taylor Cancer Research Center, Maumee
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06369285BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06120283Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020), Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- University of Cincinnati Medical Center, Cincinnati
- University of Cincinnati Medical Center - West Chester Hospital, West Chester
In reclutamentoFase 3
Età 60 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Cincinnati
- Research Site, Cincinnati
- Research Site, Cleveland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Gabrail Cancer Center, Canton
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Cincinnati
- Clinical Trial Site, Columbus
- Clinical Trial Site, Columbus
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Cleveland Clinic, Cleveland
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Cleveland Clinic Akron General, Akron
- Gabrail Cancer Center, Canton
- University Hospitals Cleveland Medical Center, Cleveland
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Miami Valley Hospital South, Centerville
- MetroHealth, Cleveland
- Cleveland Clinic, Cleveland
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland
In reclutamento
Età da 18 a 65 · Donne · Aggiornato il 15 set 2026 · NCT04362826A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University Hospital Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Miami Valley Hospital South, Centerville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT05386108A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Cleveland Clinic Foundation, Cleveland
- The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc., Columbus
In reclutamentoFase 1
Età da 18 a 55 · Donne · Aggiornato il 9 set 2026 · NCT07310420A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Cincinnati Medical Center, Cincinnati
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07287917Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- University of Cincinnati Medical Center, Cincinnati
In reclutamentoStudio osservazionale
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Hillcrest Hospital, Mayfield Heights
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Summa Health System - Akron Campus, Akron
- Aultman Alliance Community Hospital, Alliance
- OhioHealth O'Bleness Hospital, Athens
- e altri 39
In reclutamentoFase 3
Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Gabrail Cancer & Research Center, Canton
- Cleveland Clinic, Cleveland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07029399A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06774963ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Stefanie Spielman Comprehensive Breast Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT04893109Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06500481Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
In reclutamentoFase 2
Età 19 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06129747Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Oncology Hematology Care, Cincinnati
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT05232916Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2Volontari sani benvenuti
Età da 45 a 74 · Donne · Aggiornato il 4 ago 2026 · NCT06195306Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Indu and Raj Soin Medical Center, Beavercreek
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- e altri 16
In reclutamentoFase 3
Età da 18 a 50 · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT06748222Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- Case Western Reserve University, Cleveland
In reclutamentoFase 2
Età da 18 a 55 · Donne · Aggiornato il 27 lug 2026 · NCT06184750A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
In reclutamentoFase 2
Età 8 e oltre · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05503797TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
- Case Western Reserve University/University Hospitals Cleveland, Cleveland
In reclutamento
Età 65 e oltre · Donne · Aggiornato il 17 lug 2026 · NCT05535192Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.